T cell

T cell
T cell
	Animation of T cell
	Scanning electron micrograph of ared blood cell(left), aplatelet(center), and a T lymphocyte (right); colorized
Details
System	Immune system
Identifiers
Latin	lymphocytus T
MeSH	D013601
TH	H2.00.04.1.02007
FMA	62870
	Anatomical terms of microanatomy [edit on Wikidata]

T cellsare one of the important types ofwhite blood cellsof theimmune systemand play a central role in theadaptive immune response.T cells can be distinguished from otherlymphocytesby the presence of aT-cell receptor(TCR) on theircell surface.

T cells are born fromhematopoietic stem cells,^[1]found in thebone marrow.Developing T cells then migrate to thethymusgland to develop (or mature). T cells derive their name from thethymus.^[2]^[3]After migration to the thymus, the precursor cells mature into several distinct types of T cells. T cell differentiation also continues after they have left the thymus. Groups of specific, differentiated T cell subtypes have a variety of important functions in controlling and shaping theimmune response.

One of these functions is immune-mediated cell death, and it is carried out by two major subtypes:CD8+ "killer"(cytotoxic) andCD4+ "helper"T cells. (These are named for the presence of the cell surface proteinsCD8orCD4.) CD8+ T cells, also known as "killer T cells", arecytotoxic– this means that they are able to directly kill virus-infected cells, as well as cancer cells. CD8+ T cells are also able to use small signalling proteins, known ascytokines,to recruit other types of cells when mounting an immune response. A different population of T cells, the CD4+ T cells, function as "helper cells". Unlike CD8+ killer T cells, the CD4+ helper T (T_H) cells function by further activatingmemory B cellsand cytotoxic T cells, which leads to a larger immune response. The specific adaptive immune response regulated by the T_Hcell depends on its subtype (such as T-helper1, T-helper2, T-helper17, regulatory T-cell),^[4]which is distinguished by the types of cytokines they secrete.^[2]

Regulatory T cellsare yet another distinct population of T cells that provide the critical mechanism oftolerance,wherebyimmune cellsare able to distinguish invading cells from "self". This prevents immune cells from inappropriately reacting against one's own cells, known as an "autoimmune"response. For this reason, these regulatory T cells have also been called" suppressor "T cells. These same regulatory T cells can also be co-opted by cancer cells to prevent the recognition of, and an immune response against, tumor cells.

Development[edit]

Origin, early development and migration to the thymus[edit]

All T cells originate from c-kit⁺Sca1⁺haematopoietic stem cells(HSC) which reside in the bone marrow. In some cases, the origin might be the fetalliverduringembryonic development.The HSC then differentiate into multipotent progenitors (MPP) which retain the potential to become bothmyeloidandlymphoid cells.The process of differentiation then proceeds to a common lymphoid progenitor (CLP), which can only differentiate into T, B or NK cells.^[5]These CLP cells then migrate via the blood to the thymus, where theyengraft:.Henceforth they are known asthymocytes,the immature stage of a T cell.

The earliest cells which arrived in the thymus are commonly termeddouble-negative,as they express neither theCD4norCD8co-receptor. The newly arrived CLP cells are CD4⁻CD8⁻CD44⁺CD25⁻ckit⁺cells, and are termed early thymic progenitor (ETP) cells.^[6]These cells will then undergo a round of division anddownregulatec-kit and are termeddouble-negative one(DN1) cells. To become T cells, the thymocytes must undergo multiple DN stages as well as positive selection and negative selection.

Double negative thymocytes can be identified by the surface expression ofCD2,CD5andCD7.Still during the double negative stages,CD34expression stops andCD1is expressed. Expression of both CD4 and CD8 makes themdouble positive,and matures into either CD4+ or CD8+ cells.

TCR development[edit]

A critical step in T cell maturation is making a functional T cell receptor (TCR). Each mature T cell will ultimately contain a unique TCR that reacts to a random pattern, allowing the immune system to recognize many different types ofpathogens.This process is essential in developing immunity to threats that the immune system has not encountered before, since due to random variation there will always be at least one TCR to match any new pathogen.

A thymocyte can only become an active T cell when it survives the process of developing a functional TCR. The TCR consists of two major components, the alpha and beta chains. These both contain random elements designed to produce a wide variety of different TCRs, but due to this huge variety they must be tested to make sure they work at all. First, the thymocytes attempt to create a functional beta chain, testing it against a 'mock' alpha chain. Then they attempt to create a functional alpha chain. Once a working TCR has been produced, the cells then must test if their TCR will identify threats correctly, and to do this it is required to recognize the body’smajor histocompatibility complex(MHC) in a process known as positive selection. The thymocyte must also ensure that it does not react adversely to "self"antigens,called negative selection. If both positive and negative selection are successful, the TCR becomes fully operational and the thymocyte becomes a T cell.

TCR β-chain selection[edit]

At the DN2 stage (CD44⁺CD25⁺), cells upregulate the recombination genes RAG1 and RAG2 and re-arrange theTCRβlocus, combiningV-D-J recombinationand constant region genes in an attempt to create a functional TCRβ chain. As the developing thymocyte progresses through to the DN3 stage (CD44⁻CD25⁺), the thymocyte expresses an invariant α-chain called pre-Tα alongside the TCRβ gene. If the rearranged β-chain successfully pairs with the invariant α-chain, signals are produced which cease rearrangement of the β-chain (and silence the alternate allele).^[7]Although these signals require the pre-TCR at the cell surface, they are independent of ligand binding to the pre-TCR. If the chains successfully pair a pre-TCR forms, and the cell downregulates CD25 and is termed a DN4 cell (CD25⁻CD44⁻). These cells then undergo a round of proliferation, and begin to re-arrange the TCRα locus during thedouble-positivestage.

Positive selection[edit]

The process of positive selection takes 3 to 4 days and occurs in the thymic cortex.^[8]Double-positive thymocytes (CD4⁺/CD8⁺) migrate deep into thethymic cortex,where they are presented with self-antigens.These self-antigens are expressed bythymic cortical epithelial cellson MHC molecules, which reside on the surface of cortical epithelial cells. Only thymocytes that interact well with MHC-I or MHC-II will receive a vital "survival signal", while those that cannot interact strongly enough will receive no signal and die from neglect. This process ensures that the surviving thymocytes will have an 'MHC affinity' that means they can serve useful functions in the body, responding to MHC molecules to assist immune responses. The vast majority of developing thymocytes will not pass positive selection, and die during this process.^[9]

A thymocyte's fate is determined during positive selection. Double-positive cells (CD4⁺/CD8⁺) that interact well with MHCclass IImolecules will eventually become CD4⁺"helper" cells, whereas thymocytes that interact well with MHCclass Imolecules mature into CD8⁺"killer" cells. A thymocyte becomes a CD4⁺cell by down-regulating expression of its CD8 cell surface receptors. If the cell does not lose its signal, it will continue downregulating CD8 and become a CD4⁺,both CD8⁺and CD4⁺cells are nowsingle positivecells.^[10]

This process does not filter for thymocytes that may causeautoimmunity.The potentially autoimmune cells are removed by the following process of negative selection, which occurs in the thymic medulla.

Negative selection[edit]

Negative selection removes thymocytes that are capable of strongly binding with "self" MHC molecules. Thymocytes that survive positive selection migrate towards the boundary of the cortex and medulla in the thymus. While in the medulla, they are again presented with a self-antigen presented on the MHC complex ofmedullary thymic epithelial cells(mTECs).^[11]mTECs must beAutoimmune regulatorpositive (AIRE⁺) to properly express self-antigens from all tissues of the body on their MHCclass Ipeptides. Some mTECs arephagocytosedbythymic dendritic cells;this makes them AIRE⁻antigen presenting cells(APCs), allowing for presentation of self-antigens on MHCclass IImolecules (positively selected CD4⁺cells must interact with these MHC class II molecules, thus APCs, which possess MHC class II, must be present for CD4⁺T-cell negative selection). Thymocytes that interact too strongly with the self-antigen receive anapoptoticsignal that leads to cell death. However, some of these cells are selected to becomeTregcells. The remaining cells exit the thymus as maturenaive T cells,also known as recent thymic emigrants.^[12]This process is an important component ofcentral toleranceand serves to prevent the formation of self-reactive T cells that are capable of inducing autoimmune diseases in the host.

TCR development summary[edit]

β-selection is the first checkpoint, where thymocytes that are able to form a functional pre-TCR (with an invariant alpha chain and a functional beta chain) are allowed to continue development in the thymus. Next, positive selection checks that thymocytes have successfully rearranged their TCRα locus and are capable of recognizing MHC molecules with appropriate affinity. Negative selection in the medulla then eliminates thymocytes that bind too strongly to self-antigens expressed on MHC molecules. These selection processes allow for tolerance of self by the immune system. Typical naive T cells that leave the thymus (via the corticomedullary junction) are self-restricted, self-tolerant, and single positive.

Thymic output[edit]

About 98% of thymocytes die during the development processes in the thymus by failing either positive selection or negative selection, whereas the other 2% survive and leave the thymus to become mature immunocompetent T cells.^[13] The thymus contributes fewer cells as a person ages. As the thymus shrinks by about 3%^[14]a year throughout middle age, a corresponding fall in the thymic production of naive T cells occurs, leaving peripheral T cell expansion and regeneration to play a greater role in protecting older people.

Types of T cell[edit]

T cells are grouped into a series of subsets based on their function. CD4 and CD8 T cells are selected in the thymus, but undergo further differentiation in the periphery to specialized cells which have different functions. T cell subsets were initially defined by function, but also have associated gene or protein expression patterns.

Conventional adaptive T cells[edit]

Helper CD4+ T cells[edit]

T helper cells(T_Hcells) assist other lymphocytes, including the maturation ofB cellsintoplasma cellsandmemory B cells,and activation ofcytotoxic T cellsandmacrophages.These cells are also known asCD4⁺T cellsas they express theCD4glycoprotein on their surfaces. Helper T cells become activated when they are presented withpeptide antigensbyMHC class IImolecules, which are expressed on the surface ofantigen-presenting cells(APCs). Once activated, they divide rapidly and secretecytokinesthat regulate or assist the immune response. These cells can differentiate into one of several subtypes, which have different roles. Cytokines direct T cells into particular subtypes.^[15]

CD4+ Helper T cell subsets
Cell type	Cytokines Produced	Key Transcription Factor	Role in immune defense	Related diseases
Th1	IFNγ,IL-2	Tbet	Produce an inflammatory response, key for defense against intracellular bacteria, viruses and cancer.	MS, Type 1 diabetes
Th2	IL-4, IL-5, IL-13	GATA-3	Immunologically important against extracellular pathogens, such as worm infections	Asthma and other allergic diseases
Th17	IL-17F, IL-17A, IL-22	RORγt	Defense against gut pathogens and at mucosal barriers	MS, Rheumatoid Arthritis, Psoriasis
Th9^[16]^[17]	IL-9	IRF4, PU.1	Defense against helminths (parasitic worms) and cell-dependent allergic inflammation	Multiple Sclerosis
Tfh	IL-21, IL-4	Bcl-6	Help B cells produce antibodies	Asthma and other allergic diseases
Th22^[18]^[17]	IL-22	AHR	Pathogenesis of allergic airway diseases and predominantly anti-inflammatory	Crohn's Disease, Rheumatoid Arthritis, Tumors

Cytotoxic CD8+ T cells[edit]

Cytotoxic T cells(T_Ccells, CTLs, T-killer cells, killer T cells) destroy virus-infected cells and tumor cells, and are also implicated intransplantrejection. These cells are defined by the expression of theCD8protein on their cell surface. Cytotoxic T cells recognize their targets by binding to short peptides (8-11amino acidsin length) associated withMHC class Imolecules, present on the surface of all nucleated cells. Cytotoxic T cells also produce the key cytokines IL-2 and IFNγ. These cytokines influence the effector functions of other cells, in particular macrophages and NK cells.

Memory T cells[edit]

Antigen-naive T cells expand and differentiate into memory andeffector T cellsafter they encounter their cognate antigen within the context of an MHC molecule on the surface of a professional antigen presenting cell (e.g. a dendritic cell). Appropriate co-stimulation must be present at the time of antigen encounter for this process to occur. Historically, memory T cells were thought to belong to either the effector or central memory subtypes, each with their own distinguishing set of cell surface markers (see below).^[19]Subsequently, numerous new populations of memory T cells were discovered including tissue-resident memory T (Trm) cells, stem memory TSCM cells, and virtual memory T cells. The single unifying theme for allmemory T cellsubtypes is that they are long-lived and can quickly expand to large numbers of effector T cells upon re-exposure to their cognate antigen. By this mechanism they provide the immune system with "memory" against previously encountered pathogens. Memory T cells may be either CD4⁺or CD8⁺and usually expressCD45RO.^[20]

Memory T cell subtypes:

Central memory T cells (T_CMcells) express CD45RO,C-C chemokine receptor type 7(CCR7), andL-selectin(CD62L). Central memory T cells also have intermediate to high expression ofCD44.This memory subpopulation is commonly found in thelymph nodesand in the peripheral circulation. (Note- CD44 expression is usually used to distinguish murine naive from memory T cells).
Effector memory T cells (T_EMcells and T_EMRAcells) express CD45RO but lack expression of CCR7 andL-selectin.They also have intermediate to high expression ofCD44.These memory T cells lack lymph node-homing receptors and are thus found in the peripheral circulation and tissues.^[21]T_EMRAstands for terminally differentiated effector memory cells re-expressing CD45RA, which is a marker usually found on naive T cells.^[22]
Tissue-resident memory T cells(T_RM) occupy tissues (skin, lung, etc.) without recirculating. One cell surface marker that has been associated with T_RMis the intern αeβ7, also known as CD103.^[23]
Virtual memory T cells(T_VM) differ from the other memory subsets in that they do not originate following a strong clonal expansion event. Thus, although this population as a whole is abundant within the peripheral circulation, individual virtual memory T cell clones reside at relatively low frequencies. One theory is that homeostatic proliferation gives rise to this T cell population. Although CD8 virtual memory T cells were the first to be described,^[24]it is now known that CD4 virtual memory cells also exist.^[25]

Regulatory CD4+ T cells[edit]

Regulatory T cellsare crucial for the maintenance ofimmunological tolerance.Their major role is to shut down T cell–mediated immunity toward the end of an immune reaction and to suppressautoreactive T cellsthat escaped the process of negative selection in the thymus.

Two major classes of CD4⁺T_regcells have been described—FOXP3⁺T_regcells and FOXP3⁻T_regcells.

Regulatory T cells can develop either during normal development in the thymus, and are then known as thymic Treg cells, or can be induced peripherally and are called peripherally derived Treg cells. These two subsets were previously called "naturally occurring" and "adaptive" (or "induced" ), respectively.^[26]Both subsets require the expression of thetranscription factor FOXP3which can be used to identify the cells. Mutations of theFOXP3gene can prevent regulatory T cell development, causing the fatalautoimmune disease IPEX.

Several other types of T cells have suppressive activity, but do not express FOXP3 constitutively. These includeTr1andTh3cells, which are thought to originate during an immune response and act by producing suppressive molecules. Tr1 cells are associated with IL-10, and Th3 cells are associated withTGF-beta.Recently,Th17 cellshave been added to this list.^[27]

Innate-like T cells[edit]

Innate-like T cellsorunconventional T cellsrepresent some subsets of T cells that behave differently in immunity. They trigger rapid immune responses, regardless of the major histocompatibility complex (MHC) expression, unlike their conventional counterparts (CD4 T helper cells and CD8 cytotoxic T cells), which are dependent on the recognition of peptide antigens in the context of the MHC molecule. Overall, there are three large populations of unconventional T cells: NKT cells, MAIT cells, and gammadelta T cells. Now, their functional roles are already being well established in the context of infections and cancer.^[28]Furthermore, these T cell subsets are being translated into many therapies against malignancies such as leukemia, for example.^[29]

Natural killer T cell[edit]

Natural killer T cells(NKT cells – not to be confused withnatural killer cellsof the innate immune system) bridge theadaptive immune systemwith theinnate immune system.Unlike conventional T cells that recognize protein peptide antigens presented bymajor histocompatibility complex(MHC) molecules, NKT cells recognize glycolipid antigens presented byCD1d.Once activated, these cells can perform functions ascribed to both helper and cytotoxic T cells: cytokine production and release of cytolytic/cell killing molecules. They are also able to recognize and eliminate some tumor cells and cells infected with herpes viruses.^[30]

Mucosal associated invariant T cells[edit]

Mucosal associated invariant T (MAIT) cells displayinnate,effector-like qualities.^[31]^[32]In humans, MAIT cells are found in the blood, liver, lungs, andmucosa,defending against microbial activity and infection.^[31]TheMHC class I-like protein,MR1,is responsible for presenting bacterially-producedvitamin Bmetabolites to MAIT cells.^[33]^[34]^[35]After the presentation of foreign antigen by MR1, MAIT cells secrete pro-inflammatorycytokinesand are capable oflysingbacterially-infected cells.^[31]^[35]MAIT cells can also be activated through MR1-independent signaling.^[35]In addition to possessing innate-like functions, this T cell subset supports theadaptiveimmune response and has a memory-like phenotype.^[31]Furthermore, MAIT cells are thought to play a role inautoimmune diseases,such asmultiple sclerosis,arthritis andinflammatory bowel disease,^[36]^[37]although definitive evidence is yet to be published.^[38]^[39]^[40]^[41]

Gamma delta T cells[edit]

Gamma delta T cells(γδ T cells) represent a small subset of T cells which possess a γδ TCR rather than the αβ TCR on the cell surface. The majority of T cells express αβ TCR chains. This group of T cells is much less common in humans and mice (about 2% of total T cells) and are found mostly in the gutmucosa,within a population ofintraepithelial lymphocytes.In rabbits, sheep, and chickens, the number of γδ T cells can be as high as 60% of total T cells. The antigenic molecules that activate γδ T cells are still mostly unknown. However, γδ T cells are not MHC-restricted and seem to be able to recognize whole proteins rather than requiring peptides to be presented by MHC molecules onAPCs.Somemurineγδ T cells recognize MHC class IB molecules. Human γδ T cells that use the Vγ9 and Vδ2 gene fragments constitute the major γδ T cell population in peripheral blood. These cells are unique in that they specifically and rapidly respond to a set of nonpeptidic phosphorylatedisoprenoidprecursors, collectively namedphosphoantigens,which are produced by virtually all living cells. The most common phosphoantigens from animal and human cells (including cancer cells) areisopentenyl pyrophosphate(IPP) and its isomerdimethylallyl pyrophosphate(DMPP). Many microbes produce the active compound hydroxy-DMAPP (HMB-PP) and corresponding mononucleotide conjugates, in addition to IPP and DMAPP. Plant cells produce both types of phosphoantigens. Drugs activating human Vγ9/Vδ2 T cells comprise synthetic phosphoantigens andaminobisphosphonates,which upregulate endogenous IPP/DMAPP.

Activation[edit]

Activation of CD4⁺T cells occurs through the simultaneous engagement of theT-cell receptorand a co-stimulatory molecule (likeCD28,orICOS) on the T cell by the major histocompatibility complex (MHCII)peptideand co-stimulatory molecules on theAPC.Both are required for production of an effective immune response; in the absence ofco-stimulation,T cell receptor signalling alone results inanergy.The signalling pathways downstream from co-stimulatory molecules usually engages thePI3Kpathway generatingPIP3at the plasma membrane and recruitingPH domaincontaining signaling molecules likePDK1that are essential for the activation ofPKC-θ,and eventualIL-2production. Optimal CD8⁺T cell response relies on CD4⁺signalling.^[43]CD4⁺cells are useful in the initial antigenic activation of naive CD8 T cells, and sustaining memory CD8⁺T cells in the aftermath of an acute infection. Therefore, activation of CD4⁺T cells can be beneficial to the action of CD8⁺T cells.^[44]^[45]^[46]

The first signal is provided by binding of the T cell receptor to its cognate peptide presented on MHCII on an APC. MHCII is restricted to so-called professionalantigen-presenting cells,like dendritic cells, B cells, and macrophages, to name a few. The peptides presented to CD8⁺T cells by MHC class I molecules are 8–13 amino acids in length; the peptides presented to CD4⁺cells by MHC class II molecules are longer, usually 12–25 amino acids in length,^[47]as the ends of the binding cleft of the MHC class II molecule are open.

The second signal comes from co-stimulation, in which surface receptors on the APC are induced by a relatively small number of stimuli, usually products of pathogens, but sometimes breakdown products of cells, such asnecrotic-bodies orheat shock proteins.The only co-stimulatory receptor expressed constitutively by naive T cells is CD28, so co-stimulation for these cells comes from theCD80andCD86proteins, which together constitute theB7protein, (B7.1 and B7.2, respectively) on the APC. Other receptors are expressed upon activation of the T cell, such asOX40and ICOS, but these largely depend upon CD28 for their expression. The second signal licenses the T cell to respond to an antigen. Without it, the T cell becomesanergic,and it becomes more difficult for it to activate in future. This mechanism prevents inappropriate responses to self, as self-peptides will not usually be presented with suitable co-stimulation. Once a T cell has been appropriately activated (i.e. has received signal one and signal two) it alters its cell surface expression of a variety of proteins. Markers of T cell activation include CD69, CD71 and CD25 (also a marker for Treg cells), and HLA-DR (a marker of human T cell activation). CTLA-4 expression is also up-regulated on activated T cells, which in turn outcompetes CD28 for binding to the B7 proteins. This is a checkpoint mechanism to prevent over activation of the T cell. Activated T cells also change their cell surface glycosylation profile.^[48]

TheT cell receptorexists as a complex of several proteins. The actual T cell receptor is composed of two separate peptide chains, which are produced from the independent T cell receptor alpha and beta (TCRαandTCRβ) genes. The other proteins in the complex are theCD3proteins: CD3εγ and CD3εδ heterodimers and, most important, a CD3ζ homodimer, which has a total of sixITAMmotifs. The ITAM motifs on the CD3ζ can be phosphorylated byLckand in turn recruitZAP-70.Lck and/or ZAP-70 can also phosphorylate thetyrosineson many other molecules, not least CD28,LATandSLP-76,which allows the aggregation of signalling complexes around these proteins.

PhosphorylatedLATrecruits SLP-76 to the membrane, where it can then bring inPLC-γ,VAV1,Itkand potentiallyPI3K.PLC-γ cleaves PI(4,5)P2 on the inner leaflet of the membrane to create the active intermediaries diacylglycerol (DAG), inositol-1,4,5-trisphosphate (IP3); PI3K also acts on PIP2, phosphorylating it to produce phosphatidlyinositol-3,4,5-trisphosphate (PIP3). DAG binds and activates some PKCs. Most important in T cells is PKC-θ, critical for activating the transcription factorsNF-κBand AP-1.IP3is released from the membrane by PLC-γ and diffuses rapidly to activate calcium channel receptors on theER,which induces the release ofcalciuminto the cytosol. Low calcium in the endoplasmic reticulum causes STIM1 clustering on the ER membrane and leads to activation of cell membrane CRAC channels that allows additional calcium to flow into the cytosol from the extracellular space. This aggregated cytosolic calcium binds calmodulin, which can then activatecalcineurin.Calcineurin, in turn, activatesNFAT,which then translocates to the nucleus. NFAT is atranscription factorthat activates the transcription of a pleiotropic set of genes, most notable, IL-2, a cytokine that promotes long-term proliferation of activated T cells.

PLC-γ can also initiate theNF-κB pathway.DAG activates PKC-θ, which then phosphorylates CARMA1, causing it to unfold and function as a scaffold. The cytosolic domains bind an adapterBCL10viaCARD(Caspase activation and recruitment domains) domains; that then binds TRAF6, which is ubiquitinated at K63.^{: 513–523}^[49]This form of ubiquitination does not lead to degradation of target proteins. Rather, it serves to recruit NEMO, IKKα and -β, and TAB1-2/ TAK1.^[50]TAK 1 phosphorylates IKK-β, which then phosphorylates IκB allowing for K48 ubiquitination: leads to proteasomal degradation. Rel A and p50 can then enter the nucleus and bind the NF-κB response element. This coupled with NFAT signaling allows for complete activation of the IL-2 gene.^[49]

While in most cases activation is dependent on TCR recognition of antigen, alternative pathways for activation have been described. For example, cytotoxic T cells have been shown to become activated when targeted by other CD8 T cells leading to tolerization of the latter.^[51]

In spring 2014, theT-Cell Activation in Space(TCAS) experiment was launched to theInternational Space Stationon theSpaceX CRS-3mission to study how "deficiencies in the human immune system are affected by a microgravity environment".^[52]

T cell activation is modulated byreactive oxygen species.^[53]

Antigen discrimination[edit]

A unique feature of T cells is their ability to discriminate between healthy and abnormal (e.g. infected or cancerous) cells in the body.^[54]Healthy cells typically express a large number of self derivedpMHCon their cell surface and although the T cell antigen receptor can interact with at least a subset of these self pMHC, the T cell generally ignores these healthy cells. However, when these very same cells contain even minute quantities of pathogen derived pMHC, T cells are able to become activated and initiate immune responses. The ability of T cells to ignore healthy cells but respond when these same cells contain pathogen (or cancer) derived pMHC is known as antigen discrimination. The molecular mechanisms that underlie this process are controversial.^[54]^[55]

Clinical significance[edit]

Deficiency[edit]

Causes ofT cell deficiencyincludelymphocytopeniaof T cells and/or defects on function of individual T cells. Complete insufficiency of T cell function can result fromhereditary conditionssuch assevere combined immunodeficiency(SCID),Omenn syndrome,andcartilage–hair hypoplasia.^[56]Causes of partial insufficiencies of T cell function includeacquired immune deficiency syndrome(AIDS), and hereditary conditions such asDiGeorge syndrome(DGS),chromosomal breakage syndromes(CBSs), and B cell and T cell combined disorders such asataxia-telangiectasia(AT) andWiskott–Aldrich syndrome(WAS).^[56]

The main pathogens of concern in T cell deficiencies areintracellular pathogens,includingHerpes simplex virus,MycobacteriumandListeria.^[57]Also,fungal infectionsare also more common and severe in T cell deficiencies.^[57]

Cancer[edit]

Cancerof T cells is termedT-cell lymphoma,and accounts for perhaps one in ten cases ofnon-Hodgkin lymphoma.^[58]The main forms of T cell lymphoma are:

Exhaustion[edit]

T cell exhaustion is a poorly defined or ambiguous term.^[59]^[60]There are three approaches to its definition.^[59]"The first approach primarily defines as exhausted the cells that present the same cellular dysfunction (typically, the absence of an expected effector response). The second approach primarily defines as exhausted the cells that are produced by a given cause (typically, but not necessarily, chronic exposure to an antigen). Finally, the third approach primarily defines as exhausted the cells that present the same molecular markers (typically, programmed cell death protein 1 [PD-1])."^[59]

Dysfunctional T cells are characterized by progressive loss of function, changes in transcriptional profiles and sustained expression of inhibitory receptors. At first, cells lose their ability to produceIL-2andTNFα,which is followed by the loss of high proliferative capacity and cytotoxic potential, and eventually leads to their deletion. Exhausted T cells typically indicate higher levels ofCD43,CD69and inhibitory receptors combined with lower expression ofCD62LandCD127.Exhaustion can develop during chronic infections, sepsis and cancer.^[61]Exhausted T cells preserve their functional exhaustion even after repeated antigen exposure.^[62]

During chronic infection and sepsis[edit]

T cell exhaustion can be triggered by several factors like persistent antigen exposure and lack of CD4 T cell help.^[63]Antigen exposure also has effect on the course of exhaustion because longer exposure time and higher viral load increases the severity of T cell exhaustion. At least 2–4 weeks exposure is needed to establish exhaustion.^[64]Another factor able to induce exhaustion are inhibitory receptors includingprogrammed cell death protein 1(PD1),CTLA-4,T cell membrane protein-3 (TIM3), andlymphocyte activation gene 3 protein(LAG3).^[65]^[66]Soluble molecules such as cytokinesIL-10orTGF-βare also able to trigger exhaustion.^[67]^[68]Last known factors that can play a role in T cell exhaustion are regulatory cells.Tregcells can be a source of IL-10 and TGF-β and therefore they can play a role in T cell exhaustion.^[69]Furthermore, T cell exhaustion is reverted after depletion of Treg cells and blockade of PD1.^[70]T cell exhaustion can also occur during sepsis as a result of cytokine storm. Later after the initial septic encounter anti-inflammatory cytokines and pro-apoptotic proteins take over to protect the body from damage. Sepsis also carries high antigen load and inflammation. In this stage of sepsis T cell exhaustion increases.^[71]^[72]Currently there are studies aiming to utilize inhibitory receptor blockades in treatment of sepsis.^[73]^[74]^[75]

During transplantation[edit]

While during infection T cell exhaustion can develop following persistent antigen exposure after graft transplant similar situation arises with alloantigen presence.^[76]It was shown that T cell response diminishes over time after kidney transplant.^[77]These data suggest T cell exhaustion plays an important role in tolerance of a graft mainly by depletion of alloreactive CD8 T cells.^[72]^[78]Several studies showed positive effect of chronic infection on graft acceptance and its long-term survival mediated partly by T cell exhaustion.^[79]^[80]^[81]It was also shown that recipient T cell exhaustion provides sufficient conditions forNK celltransfer.^[82]While there are data showing that induction of T cell exhaustion can be beneficial for transplantation it also carries disadvantages among which can be counted increased number of infections and the risk of tumor development.^[83]

During cancer[edit]

During cancer T cell exhaustion plays a role in tumor protection. According to research some cancer-associated cells as well as tumor cells themselves can actively induce T cell exhaustion at the site of tumor.^[84]^[85]^[86]T cell exhaustion can also play a role in cancer relapses as was shown on leukemia.^[87]Some studies have suggested that it is possible to predict relapse of leukemia based on expression of inhibitory receptors PD-1 and TIM-3 by T cells.^[88]Many experiments and clinical trials have focused on immune checkpoint blockers in cancer therapy, with some of these approved as valid therapies that are now in clinical use.^[89]Inhibitory receptors targeted by those medical procedures are vital in T cell exhaustion and blocking them can reverse these changes.^[90]

References[edit]

^"5. Hematopoietic Stem Cells".Stem Cell Information.Bethesda, MD: National Institutes of Health, U.S. Department of Health and Human Services. 17 June 2001. Archived fromthe originalon 29 October 2016.Retrieved21 December2021.
^^a ^bAlberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P (2002)."Helper T Cells and Lymphocyte Activation".Molecular Biology of the Cell(4th ed.). Garland Science.
^Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P (2002)."Helper t Cells and Lymphocyte Activation".Molecular Biology of the Cell(4th ed.). Garland Science. p. 1367.T cells... derive their [name] from the organs in which they develop. T cells develop [mature] in the thymus
^Luckheeram RV, Zhou R, Verma AD, Xia B (2012)."CD4⁺T cells: differentiation and functions".Clinical & Developmental Immunology.2012:925135.doi:10.1155/2012/925135.PMC3312336.PMID 22474485.
^Kondo M (December 2016)."One Niche to Rule Both Maintenance and Loss of Stemness in HSCs".Immunity.45(6): 1177–1179.doi:10.1016/j.immuni.2016.12.003.PMID 28002722.
^Osborne LC, Dhanji S, Snow JW, Priatel JJ, Ma MC, Miners MJ, et al. (March 2007)."Impaired CD8 T cell memory and CD4 T cell primary responses in IL-7R alpha mutant mice".The Journal of Experimental Medicine.204(3): 619–631.doi:10.1084/jem.20061871.PMC2137912.PMID 17325202.
^Murphy, Kenneth (2011).Janeway's Immunobiology(8th ed.). Garland Science. pp. 301–305.ISBN 9780815342434.
^Ross JO, Melichar HJ, Au-Yeung BB, Herzmark P, Weiss A, Robey EA (June 2014)."Distinct phases in the positive selection of CD8+ T cells distinguished by intrathymic migration and T-cell receptor signaling patterns".Proceedings of the National Academy of Sciences of the United States of America.111(25): E2550–E2558.Bibcode:2014PNAS..111E2550R.doi:10.1073/pnas.1408482111.PMC4078834.PMID 24927565.
^Starr TK, Jameson SC, Hogquist KA (2003-01-01). "Positive and negative selection of T cells".Annual Review of Immunology.21(1): 139–176.doi:10.1146/annurev.immunol.21.120601.141107.PMID 12414722.
^Zerrahn J, Held W, Raulet DH (March 1997)."The MHC reactivity of the T cell repertoire prior to positive and negative selection".Cell.88(5): 627–636.doi:10.1016/S0092-8674(00)81905-4.PMID 9054502.S2CID 15983629.
^Hinterberger M, Aichinger M, Prazeres da Costa O, Voehringer D, Hoffmann R, Klein L (June 2010)."Autonomous role of medullary thymic epithelial cells in central CD4(+) T cell tolerance"(PDF).Nature Immunology.11(6): 512–519.doi:10.1038/ni.1874.PMID 20431619.S2CID 33154019.
^Pekalski ML, García AR, Ferreira RC, Rainbow DB, Smyth DJ, Mashar M, Brady J, Savinykh N, Dopico XC, Mahmood S, Duley S, Stevens HE, Walker NM, Cutler AJ, Waldron-Lynch F, Dunger DB, Shannon-Lowe C, Coles AJ, Jones JL, Wallace C, Todd JA, Wicker LS (August 2017)."Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2".JCI Insight.2(16).doi:10.1172/jci.insight.93739.PMC5621870.PMID 28814669.
^Murphy, Kenneth (2011).Janeway's Immunobiology(8th ed.). Garland Science. p. 297.ISBN 9780815342434.
^Haynes BF, Markert ML, Sempowski GD, Patel DD, Hale LP (2000). "The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection".Annu. Rev. Immunol.18:529–560.doi:10.1146/annurev.immunol.18.1.529.PMID 10837068.
^Gutcher I, Becher B (2007)."APC-derived cytokines and T cell polarization in autoimmune inflammation".J. Clin. Invest.117(5): 1119–27.doi:10.1172/JCI31720.PMC1857272.PMID 17476341.
^Wang W, Sung N, Gilman-Sachs A, Kwak-Kim J (18 August 2020)."T Helper (Th) Cell Profiles in Pregnancy and Recurrent Pregnancy Losses: Th1/Th2/Th9/Th17/Th22/Tfh Cells".Frontiers in Immunology.11:2025.doi:10.3389/fimmu.2020.02025.PMC7461801.PMID 32973809.
^^a ^bSaravia J, Chapman NM, Chi H (July 2019)."Helper T cell differentiation".Cellular & Molecular Immunology.16(7): 634–643.doi:10.1038/s41423-019-0220-6.PMC6804569.PMID 30867582.
^Jia L, Wu C (2014). "The Biology and Functions of Th22 Cells".T Helper Cell Differentiation and Their Function.Advances in Experimental Medicine and Biology. Vol. 841. pp. 209–230.doi:10.1007/978-94-017-9487-9_8.ISBN 978-94-017-9486-2.PMID 25261209.
^Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A (1999). "Two subsets of memory T lymphocytes with distinct homing potentials and effector functions".Nature.401(6754): 708–712.Bibcode:1999Natur.401..708S.doi:10.1038/44385.PMID 10537110.S2CID 4378970.
^Akbar AN, Terry L, Timms A, Beverley PC, Janossy G (April 1988)."Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T cells".J. Immunol.140(7): 2171–8.doi:10.4049/jimmunol.140.7.2171.PMID 2965180.S2CID 22340282.
^Willinger T, Freeman T, Hasegawa H, McMichael AJ, Callan MF (2005)."Molecular signatures distinguish human central memory from effector memory CD8 T cell subsets"(PDF).Journal of Immunology.175(9): 5895–903.doi:10.4049/jimmunol.175.9.5895.PMID 16237082.S2CID 16412760.
^Koch S, Larbi A, Derhovanessian E, Özcelik D, Naumova E, Pawelec G (2008)."Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people".Immunity & Ageing.5(6): 6.doi:10.1186/1742-4933-5-6.PMC2515281.PMID 18657274.
^Shin H, Iwasaki A (September 2013)."Tissue-resident memory T cells".Immunological Reviews.255(1): 165–81.doi:10.1111/imr.12087.PMC3748618.PMID 23947354.
^Lee YJ, Jameson SC, Hogquist KA (2011)."Alternative memory in the CD8 T cell lineage".Trends in Immunology.32(2): 50–56.doi:10.1016/j.it.2010.12.004.PMC3039080.PMID 21288770.
^Marusina AI, Ono Y, Merleev AA, Shimoda M, Ogawa H, Wang EA, Kondo K, Olney L, Luxardi G, Miyamura Y, Yilma TD, Villalobos IB, Bergstrom JW, Kronenberg DG, Soulika AM, Adamopoulos IE, Maverakis E (2017)."CD4+ virtual memory: Antigen-inexperienced T cells reside in the naïve, regulatory, and memory T cell compartments at similar frequencies, implications for autoimmunity".Journal of Autoimmunity.77:76–88.doi:10.1016/j.jaut.2016.11.001.PMC6066671.PMID 27894837.
^Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S, Jiang S, Kuchroo VK, Mathis D, Roncarolo MG, Rudensky A, Sakaguchi S, Shevach EM, Vignali DA, Ziegler SF (2013)."Regulatory T cells: recommendations to simplify the nomenclature".Nat. Immunol.14(4): 307–8.doi:10.1038/ni.2554.PMID 23507634.S2CID 11294516.
^Singh B, Schwartz JA, Sandrock C, Bellemore SM, Nikoopour E (2013)."Modulation of autoimmune diseases by interleukin (IL)-17 producing regulatory T helper (Th17) cells".Indian J. Med. Res.138(5): 591–4.PMC3928692.PMID 24434314.
^Godfrey DI, Uldrich AP, McCluskey J, Rossjohn J, Moody DB (November 2015). "The burgeoning family of unconventional T cells".Nature Immunology.16(11): 1114–1123.doi:10.1038/ni.3298.PMID 26482978.S2CID 30992456.
^de Araújo ND, Gama FM, de Souza Barros M, Ribeiro TL, Alves FS, Xabregas LA, et al. (2021)."Translating Unconventional T Cells and Their Roles in Leukemia Antitumor Immunity".Journal of Immunology Research.2021:6633824.doi:10.1155/2021/6633824.PMC7808823.PMID 33506055.
^Mallevaey T, Fontaine J, Breuilh L, Paget C, Castro-Keller A, Vendeville C, Capron M, Leite-de-Moraes M, Trottein F, Faveeuw C (May 2007)."Invariant and noninvariant natural killer T cells exert opposite regulatory functions on the immune response during murine schistosomiasis".Infection and Immunity.75(5): 2171–80.doi:10.1128/IAI.01178-06.PMC1865739.PMID 17353286.
^^a ^b ^c ^dNapier RJ, Adams EJ, Gold MC, Lewinsohn DM (2015-07-06)."The Role of Mucosal Associated Invariant T Cells in Antimicrobial Immunity".Frontiers in Immunology.6:344.doi:10.3389/fimmu.2015.00344.PMC4492155.PMID 26217338.
^Gold MC, Lewinsohn DM (August 2011)."Mucosal associated invariant T cells and the immune response to infection".Microbes and Infection.13(8–9): 742–8.doi:10.1016/j.micinf.2011.03.007.PMC3130845.PMID 21458588.
^Eckle SB, Corbett AJ, Keller AN, Chen Z, Godfrey DI, Liu L, Mak JY, Fairlie DP, Rossjohn J, McCluskey J (December 2015)."Recognition of Vitamin B Precursors and Byproducts by Mucosal Associated Invariant T Cells".The Journal of Biological Chemistry.290(51): 30204–11.doi:10.1074/jbc.R115.685990.PMC4683245.PMID 26468291.
^Ussher JE, Klenerman P, Willberg CB (2014-10-08)."Mucosal-associated invariant T-cells: new players in anti-bacterial immunity".Frontiers in Immunology.5:450.doi:10.3389/fimmu.2014.00450.PMC4189401.PMID 25339949.
^^a ^b ^cHowson LJ, Salio M, Cerundolo V (2015-06-16)."MR1-Restricted Mucosal-Associated Invariant T Cells and Their Activation during Infectious Diseases".Frontiers in Immunology.6:303.doi:10.3389/fimmu.2015.00303.PMC4468870.PMID 26136743.
^Hinks TS (May 2016)."Mucosal-associated invariant T cells in autoimmunity, immune-mediated diseases and airways disease".Immunology.148(1): 1–12.doi:10.1111/imm.12582.PMC4819138.PMID 26778581.
^Bianchini E, De Biasi S, Simone AM, Ferraro D, Sola P, Cossarizza A, Pinti M (March 2017). "Invariant natural killer T cells and mucosal-associated invariant T cells in multiple sclerosis".Immunology Letters.183:1–7.doi:10.1016/j.imlet.2017.01.009.PMID 28119072.
^Serriari NE, Eoche M, Lamotte L, Lion J, Fumery M, Marcelo P, Chatelain D, Barre A, Nguyen-Khac E, Lantz O, Dupas JL, Treiner E (May 2014)."Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases".Clinical and Experimental Immunology.176(2): 266–74.doi:10.1111/cei.12277.PMC3992039.PMID 24450998.
^Huang S, Martin E, Kim S, Yu L, Soudais C, Fremont DH, Lantz O, Hansen TH (May 2009)."MR1 antigen presentation to mucosal-associated invariant T cells was highly conserved in evolution".Proceedings of the National Academy of Sciences of the United States of America.106(20): 8290–5.Bibcode:2009PNAS..106.8290H.doi:10.1073/pnas.0903196106.PMC2688861.PMID 19416870.
^Chua WJ, Hansen TH (November 2010)."Bacteria, mucosal-associated invariant T cells and MR1".Immunology and Cell Biology.88(8): 767–9.doi:10.1038/icb.2010.104.PMID 20733595.S2CID 27717815.
^Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, Bhati M, Chen Z, Kostenko L, Reantragoon R, Williamson NA, Purcell AW, Dudek NL, McConville MJ, O'Hair RA, Khairallah GN, Godfrey DI, Fairlie DP, Rossjohn J, McCluskey J (November 2012)."MR1 presents microbial vitamin B metabolites to MAIT cells"(PDF).Nature.491(7426): 717–23.Bibcode:2012Natur.491..717K.doi:10.1038/nature11605.PMID 23051753.S2CID 4419703.
^TheNIAIDresource booklet"Understanding the Immune System (pdf)".
^Williams MA, Bevan MJ (2007-01-01). "Effector and memory CTL differentiation".Annual Review of Immunology.25(1): 171–92.doi:10.1146/annurev.immunol.25.022106.141548.PMID 17129182.
^Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP (February 2003). "CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes".Nature.421(6925): 852–6.Bibcode:2003Natur.421..852J.doi:10.1038/nature01441.PMID 12594515.S2CID 574770.
^Shedlock DJ, Shen H (April 2003). "Requirement for CD4 T cell help in generating functional CD8 T cell memory".Science.300(5617): 337–9.Bibcode:2003Sci...300..337S.doi:10.1126/science.1082305.PMID 12690201.S2CID 38040377.
^Sun JC, Williams MA, Bevan MJ (September 2004)."CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection".Nature Immunology.5(9): 927–33.doi:10.1038/ni1105.PMC2776074.PMID 15300249.
^Jennifer Rolland and Robyn O'Hehir, "Turning off the T cells: Peptides for treatment of allergic Diseases," Today's life science publishing, 1999, Page 32
^Maverakis E, Kim K, Shimoda M, Gershwin M, Patel F, Wilken R, Raychaudhuri S, Ruhaak LR, Lebrilla CB (2015)."Glycans in the immune system and The Altered Glycan Theory of Autoimmunity".J Autoimmun.57(6): 1–13.doi:10.1016/j.jaut.2014.12.002.PMC4340844.PMID 25578468.
^^a ^bTatham P, Gomperts BD, Kramer IM (2003).Signal transduction.Amsterdam: Elsevier Academic Press.ISBN 978-0-12-289632-3.
^Wu H, Arron JR (November 2003). "TRAF6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology".BioEssays.25(11): 1096–105.doi:10.1002/bies.10352.PMID 14579250.S2CID 28521713.
^Milstein O, Hagin D, Lask A, Reich-Zeliger S, Shezen E, Ophir E, Eidelstein Y, Afik R, Antebi YE, Dustin ML, Reisner Y (January 2011)."CTLs respond with activation and granule secretion when serving as targets for T cell recognition".Blood.117(3): 1042–52.doi:10.1182/blood-2010-05-283770.PMC3035066.PMID 21045195.
^Graham W (2014-04-14)."SpaceX ready for CRS-3 Dragon launch and new milestones".NASAspaceflight.com.Retrieved2014-04-14.
^Belikov AV, Schraven B, Simeoni L (October 2015)."T cells and reactive oxygen species".Journal of Biomedical Science.22:85.doi:10.1186/s12929-015-0194-3.PMC4608155.PMID 26471060.
^^a ^bFeinerman O, Germain RN, Altan-Bonnet G (2008)."Quantitative challenges in understanding ligand discrimination by alphabeta T cells".Mol. Immunol.45(3): 619–31.doi:10.1016/j.molimm.2007.03.028.PMC2131735.PMID 17825415.
^Dushek O, van der Merwe PA (2014)."An induced rebinding model of antigen discrimination".Trends Immunol.35(4): 153–8.doi:10.1016/j.it.2014.02.002.PMC3989030.PMID 24636916.
^^a ^bT-Cell DisordersateMedicine
^^a ^bJones J, Bannister BA, Gillespie SH, eds. (2006).Infection: Microbiology and Management.Wiley-Blackwell. p. 435.ISBN 978-1-4051-2665-6.
^"The Lymphomas"(PDF).The Leukemia & Lymphoma Society. May 2006. p. 2.Retrieved2008-04-07.
^^a ^b ^cKaminski H, Lemoine M, Pradeu T (September 2021)."Immunological exhaustion: How to make a disparate concept operational?".PLOS Pathogens.17(9): e1009892.doi:10.1371/journal.ppat.1009892.PMC8460019.PMID 34555119.
^Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, et al. (November 2019)."Defining 'T cell exhaustion'".Nature Reviews. Immunology.19(11): 665–674.doi:10.1038/s41577-019-0221-9.PMC7286441.PMID 31570879.
^Yi JS, Cox MA, Zajac AJ (April 2010)."T-cell exhaustion: characteristics, causes and conversion".Immunology.129(4): 474–81.doi:10.1111/j.1365-2567.2010.03255.x.PMC2842494.PMID 20201977.
^Wang Q, Pan W, Liu Y, Luo J, Zhu D, Lu Y, Feng X, Yang X, Dittmer U, Lu M, Yang D, Liu J (2018)."Hepatitis B Virus-Specific CD8+ T Cells Maintain Functional Exhaustion after Antigen Reexposure in an Acute Activation Immune Environment".Front Immunol.9:219.doi:10.3389/fimmu.2018.00219.PMC5816053.PMID 29483916.
^Matloubian M, Concepcion RJ, Ahmed R (December 1994)."CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection".Journal of Virology.68(12): 8056–63.doi:10.1128/JVI.68.12.8056-8063.1994.PMC237269.PMID 7966595.
^Angelosanto JM, Blackburn SD, Crawford A, Wherry EJ (August 2012)."Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection".Journal of Virology.86(15): 8161–70.doi:10.1128/JVI.00889-12.PMC3421680.PMID 22623779.
^Wherry EJ (June 2011). "T cell exhaustion".Nature Immunology.12(6): 492–9.doi:10.1038/ni.2035.PMID 21739672.S2CID 11052693.
^Okagawa T, Konnai S, Nishimori A, Maekawa N, Goto S, Ikebuchi R, Kohara J, Suzuki Y, Yamada S, Kato Y, Murata S, Ohashi K (June 2018)."+ T cells during bovine leukemia virus infection".Veterinary Research.49(1): 50.doi:10.1186/s13567-018-0543-9.PMC6006750.PMID 29914540.
^Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB (November 2006)."Interleukin-10 determines viral clearance or persistence in vivo".Nature Medicine.12(11): 1301–9.doi:10.1038/nm1492.PMC2535582.PMID 17041596.
^Tinoco R, Alcalde V, Yang Y, Sauer K, Zuniga EI (July 2009)."Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo".Immunity.31(1): 145–57.doi:10.1016/j.immuni.2009.06.015.PMC3039716.PMID 19604493.
^Veiga-Parga T, Sehrawat S, Rouse BT (September 2013)."Role of regulatory T cells during virus infection".Immunological Reviews.255(1): 182–96.doi:10.1111/imr.12085.PMC3748387.PMID 23947355.
^Penaloza-MacMaster P, Kamphorst AO, Wieland A, Araki K, Iyer SS, West EE, O'Mara L, Yang S, Konieczny BT, Sharpe AH, Freeman GJ, Rudensky AY, Ahmed R (August 2014)."Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection".The Journal of Experimental Medicine.211(9): 1905–18.doi:10.1084/jem.20132577.PMC4144726.PMID 25113973.
^Otto GP, Sossdorf M, Claus RA, Rödel J, Menge K, Reinhart K, Bauer M, Riedemann NC (July 2011)."The late phase of sepsis is characterized by an increased microbiological burden and death rate".Critical Care.15(4): R183.doi:10.1186/cc10332.PMC3387626.PMID 21798063.
^^a ^bBoomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD, Kreisel D, Krupnick AS, Srivastava A, Swanson PE, Green JM, Hotchkiss RS (December 2011)."Immunosuppression in patients who die of sepsis and multiple organ failure".JAMA.306(23): 2594–605.doi:10.1001/jama.2011.1829.PMC3361243.PMID 22187279.
^Shindo Y, McDonough JS, Chang KC, Ramachandra M, Sasikumar PG, Hotchkiss RS (February 2017)."Anti-PD-L1 peptide improves survival in sepsis".The Journal of Surgical Research.208:33–39.doi:10.1016/j.jss.2016.08.099.PMC5535083.PMID 27993215.
^Patera AC, Drewry AM, Chang K, Beiter ER, Osborne D, Hotchkiss RS (December 2016)."Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1".Journal of Leukocyte Biology.100(6): 1239–1254.doi:10.1189/jlb.4hi0616-255r.PMC5110001.PMID 27671246.
^Wei Z, Li P, Yao Y, Deng H, Yi S, Zhang C, Wu H, Xie X, Xia M, He R, Yang XP, Tang ZH (July 2018). "Alpha-lactose reverses liver injury via blockade of Tim-3-mediated CD8 apoptosis in sepsis".Clinical Immunology.192:78–84.doi:10.1016/j.clim.2018.04.010.PMID 29689313.S2CID 21657071.
^Wells AD, Li XC, Strom TB, Turka LA (May 2001)."The role of peripheral T-cell deletion in transplantation tolerance".Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences.356(1409): 617–23.doi:10.1098/rstb.2001.0845.PMC1088449.PMID 11375065.
^Halloran PF, Chang J, Famulski K, Hidalgo LG, Salazar ID, Merino Lopez M, Matas A, Picton M, de Freitas D, Bromberg J, Serón D, Sellarés J, Einecke G, Reeve J (July 2015)."Disappearance of T Cell-Mediated Rejection Despite Continued Antibody-Mediated Rejection in Late Kidney Transplant Recipients".Journal of the American Society of Nephrology.26(7): 1711–20.doi:10.1681/ASN.2014060588.PMC4483591.PMID 25377077.
^Steger U, Denecke C, Sawitzki B, Karim M, Jones ND, Wood KJ (May 2008)."Exhaustive differentiation of alloreactive CD8+ T cells: critical for determination of graft acceptance or rejection"(PDF).Transplantation.85(9): 1339–47.doi:10.1097/TP.0b013e31816dd64a.PMID 18475193.S2CID 33409478.
^de Mare-Bredemeijer EL, Shi XL, Mancham S, van Gent R, van der Heide-Mulder M, de Boer R, Heemskerk MH, de Jonge J, van der Laan LJ, Metselaar HJ, Kwekkeboom J (August 2015)."Cytomegalovirus-Induced Expression of CD244 after Liver Transplantation Is Associated with CD8+ T Cell Hyporesponsiveness to Alloantigen".Journal of Immunology.195(4): 1838–48.doi:10.4049/jimmunol.1500440.PMID 26170387.
^Gassa A, Jian F, Kalkavan H, Duhan V, Honke N, Shaabani N, Friedrich SK, Dolff S, Wahlers T, Kribben A, Hardt C, Lang PA, Witzke O, Lang KS (2016)."IL-10 Induces T Cell Exhaustion During Transplantation of Virus Infected Hearts".Cellular Physiology and Biochemistry.38(3): 1171–81.doi:10.1159/000443067.PMID 26963287.
^Shi XL, de Mare-Bredemeijer EL, Tapirdamaz Ö, Hansen BE, van Gent R, van Campenhout MJ, Mancham S, Litjens NH, Betjes MG, van der Eijk AA, Xia Q, van der Laan LJ, de Jonge J, Metselaar HJ, Kwekkeboom J (September 2015)."CMV Primary Infection Is Associated With Donor-Specific T Cell Hyporesponsiveness and Fewer Late Acute Rejections After Liver Transplantation".American Journal of Transplantation.15(9): 2431–42.doi:10.1111/ajt.13288.PMID 25943855.S2CID 5348557.
^Williams RL, Cooley S, Bachanova V, Blazar BR, Weisdorf DJ, Miller JS, Verneris MR (March 2018)."Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells".Biology of Blood and Marrow Transplantation.24(3): 618–622.doi:10.1016/j.bbmt.2017.11.022.PMC5826878.PMID 29197679.
^Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, Tangsombatvisit S, Grosso JF, Netto G, Smeltzer MP, Chaux A, Utz PJ, Workman CJ, Pardoll DM, Korman AJ, Drake CG, Vignali DA (February 2012)."Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape".Cancer Research.72(4): 917–27.doi:10.1158/0008-5472.CAN-11-1620.PMC3288154.PMID 22186141.
^Zelle-Rieser C, Thangavadivel S, Biedermann R, Brunner A, Stoitzner P, Willenbacher E, et al. (November 2016)."T cells in multiple myeloma display features of exhaustion and senescence at the tumor site".Journal of Hematology & Oncology.9(1): 116.doi:10.1186/s13045-016-0345-3.PMC5093947.PMID 27809856.
^Lakins MA, Ghorani E, Munir H, Martins CP, Shields JD (March 2018)."Cancer-associated fibroblasts induce antigen-specific deletion of CD8⁺T Cells to protect tumour cells ".Nature Communications.9(1): 948.Bibcode:2018NatCo...9..948L.doi:10.1038/s41467-018-03347-0.PMC5838096.PMID 29507342.
^Conforti L (February 2012). "The ion channel network in T lymphocytes, a target for immunotherapy".Clinical Immunology.142(2): 105–106.doi:10.1016/j.clim.2011.11.009.PMID 22189042.
^Liu L, Chang YJ, Xu LP, Zhang XH, Wang Y, Liu KY, Huang XJ (May 2018). "T cell exhaustion characterized by compromised MHC class I and II restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation".Clinical Immunology.190:32–40.doi:10.1016/j.clim.2018.02.009.PMID 29477343.
^Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Zhu L, et al. (July 2015)."PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation".Blood Cancer Journal.5(7): e330.doi:10.1038/bcj.2015.58.PMC4526784.PMID 26230954.
^"U.S. FDA Approved Immune-Checkpoint Inhibitors and Immunotherapies".Medical Writer Agency | hương cảng y học tác gia | MediPR | MediPaper Hong Kong.2018-08-21.Retrieved2018-09-22.
^Bhadra R, Gigley JP, Weiss LM, Khan IA (May 2011)."Control of Toxoplasma reactivation by rescue of dysfunctional CD8+ T-cell response via PD-1-PDL-1 blockade".Proceedings of the National Academy of Sciences of the United States of America.108(22): 9196–9201.Bibcode:2011PNAS..108.9196B.doi:10.1073/pnas.1015298108.PMC3107287.PMID 21576466.